Skip to main content
Premium Trial:

Request an Annual Quote

SQI Diagnostics, Isis Ink Immunogenicity Assay Development Deal

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

The deal covers the development of a multiplexed assay using SQI's Ig Plex multiplexing immunogenicity technology. Financial and other terms of the agreement were not disclosed.

SQI said that using its Ig Plex tests in clinical studies provides drug development firms quantitative results for multiple anti-drug antibody isotypes in one test. It also provides the use of SQI's automated systems to improve the benefits of multiplexing during a drug development's immunogenicity testing phase, and enables the drug developer to get ahead of emerging regulatory guidelines covering immunogenicity testing.

"We believe that our multiplexing solutions and services are highly complementary with Isis' extensive portfolio of drugs under development," SQI CEO Andrew Morris said in a statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.